This trial is studying the safety and effectiveness of an investigational drug called PRN473 in people with Alzheimer's disease.
- Atopic Dermatitis
2 Primary · 1 Secondary · Reporting Duration: Day 1 to Day 43
2 Treatment Groups
1 of 2
1 of 2
39 Total Participants · 2 Treatment Groups
Primary Treatment: PRN473 (SAR444727) · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 70 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What criteria must be met in order to become a participant of this research experiment?
"This experimental therapy is recruiting 40 individuals between 18 and 70 years of age that are diagnosed with dermatitis. The proper selection criteria must be met, including: having two target lesions no further than 1 point apart on the trunk or upper extremities (excluding palms), being in generally good health as judged by a medical professional, an affected body surface area of at least 1% but not more than 14%, a validated Investigator Global Assessment-atopic dermatitis score of moderate or mild at screening, if female, proof of negative pregnancy test and agreement to practice abstinence/effective contraceptive use for 4 weeks prior to visit, and stable disease with no significant" - Anonymous Online Contributor
How many healthcare facilities are administering this research?
"24 medical centres are recruiting patients for this trial, including Investigational Site Number :8400013 in Tampa, California Allergy & Asthma Medical Group-Site Number:8400008 in Los Angeles, and Florida International Research Center-Site Number:8400017 in Miami. Moreover, many other locations have joined the study as well." - Anonymous Online Contributor
Is this investigation extending recruitment to those aged 80 or over?
"This clinical trial has set the lower and upper bounds of eligible participants at 18 years old and 70, respectively." - Anonymous Online Contributor
What risks and hazards are associated with the administration of PRN473 (SAR444727)?
"Due to the lack of existing clinical data validating PRN473 (SAR444727) efficacy, its safety was judged a 2 on the scale. However, there is evidence that it can be used without causing harm." - Anonymous Online Contributor
Are there still opportunities available for individuals to join this research program?
"Currently, this medical trial is recruiting participants. It was initially advertised on August 13th 2021 with the last update being made on October 26th 2022 according to clinicaltrials.gov information." - Anonymous Online Contributor
What is the enrollment capacity for this research project?
"To commence the trial, 40 eligible participants are necessary. Principia Biopharma, a Sanofi Company is responsible for coordinating and supervising the operation of this study from sites like 8400013 in Tampa, Florida and California Allergy & Asthma Medical Group-Site Number:8400008 in Los Angeles." - Anonymous Online Contributor